Publications
385 results found
Uduku C, Pendolino V, Godsland I, et al., 2021, Cross-sectional analysis of emergency hypoglycaemia and outcome predictors among people with diabetes in an urban population, DIABETIC MEDICINE, Vol: 38, ISSN: 0742-3071
- Author Web Link
- Cite
- Citations: 1
Thomas MG, Avari P, Godsland IF, et al., 2021, Optimizing type 1 diabetes after multiple daily injections and capillary blood monitoring: Pump or sensor first? A meta-analysis using pooled differences in outcome measures, DIABETES OBESITY & METABOLISM, Vol: 23, Pages: 2521-2528, ISSN: 1462-8902
- Author Web Link
- Cite
- Citations: 7
Gimenez M, Conget I, Oliver N, 2021, Automated Insulin Delivery Systems: Today, Tomorrow and User Requirements, JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, Vol: 15, Pages: 1252-1257, ISSN: 1932-2968
- Author Web Link
- Cite
- Citations: 3
Oliver N, 2021, The power of equality, DIABETIC MEDICINE, Vol: 38, ISSN: 0742-3071
Johnson H, Godsland I, Oliver N, et al., 2021, Insight Report: Online public involvement session on the use of the Wynn Database for Metabolic Research, Insight Report: Online public involvement session on the use of the Wynn Database for Metabolic Research
Ziegler R, Oliver N, Waldenmaier D, et al., 2021, Evaluation of the Accuracy of Current Tubeless Pumps for Continuous Subcutaneous Insulin Infusion (vol 23, pg 350, 2021), DIABETES TECHNOLOGY & THERAPEUTICS, Vol: 23, Pages: 726-726, ISSN: 1520-9156
Oliver N, 2021, Keeping score, DIABETIC MEDICINE, Vol: 38, ISSN: 0742-3071
Hirani D, Unsworth R, Mahmood A, et al., 2021, A quality improvement project of a Young Adult Diabetes (YAD) service at a UK specialist centre, Publisher: KARGER, Pages: 231-232, ISSN: 1663-2818
Oliver N, 2021, Focussing care, DIABETIC MEDICINE, Vol: 38, ISSN: 0742-3071
Barnard-Kelly K, Oliver N, Thienel F, et al., 2021, Biomedical and patient reported outcomes from the PRO solo multi-national, multi-centre clinical trial, Publisher: SPRINGER, Pages: 294-295, ISSN: 0012-186X
Gehr B, Oliver N, Renard E, et al., 2021, Final data from a long-term observational study of continuous intraperitoneal insulin infusion in a vulnerable population with diabetes, Publisher: SPRINGER, Pages: 73-74, ISSN: 0012-186X
Ngaosuwan K, Johnston DG, Godsland IF, et al., 2021, Mortality risk in patients with adrenal insufficiency using prednisolone or hydrocortisone: a retrospective cohort study, Journal of Clinical Endocrinology and Metabolism, Vol: 106, Pages: 2242-2251, ISSN: 0021-972X
CONTEXT: Prednisolone has been recommended rather than hydrocortisone for glucocorticoid replacement in adrenal insufficiency due its longer duration of action and lower cost. OBJECTIVE: To determine mortality rates with prednisolone versus hydrocortisone. DESIGN: Observational study. SETTING: A UK primary care database (Clinical Practice Research Datalink). PARTICIPANTS: Patients with primary and secondary adrenal insufficiency, treated with either prednisolone or hydrocortisone, and controls individually matched for age, sex, period and place of follow-up. INTERVENTIONS: Nil. OUTCOMES: Mortality relative to individually matched controls. RESULTS: As expected, mortality in adrenal insufficiency irrespective of cause was increased, based on 5478 patients (4228 on hydrocortisone; 1250 on prednisolone) and 54314 controls (41934 and 12380, respectively). Overall, the adjusted hazard ratio (HR) was similar with the two treatments (prednisolone, 1.76 [95% CI, 1.54-2.01] vs. hydrocortisone 1.69 [1.57-1.82]; p=0.65). This was also the case for secondary adrenal insufficiency. In primary disease (1405 on hydrocortisone vs. 137 on prednisolone:13965 and 1347 controls, respectively), prednisolone-users were older, more likely to have another autoimmune disease and malignancy, and less likely to have mineralocorticoid replacement. Nevertheless, after adjustment, the HR for prednisolone-treated patients remained higher than for those taking hydrocortisone (2.92 [2.19-3.91] vs. 1.90 [1.66-2.16]; p=0.0020). CONCLUSIONS: In primary but not in secondary adrenal insufficiency mortality was higher with prednisolone. The study was large, but the number of prednisolone-treated patients was small, and they had greater risk factors. Nonetheless the increased mortality associated with prednisolone persisted despite statistical adjustment. Further evidence is needed regarding the long-term safety of prednisolone as routine replacement.
Oliver N, 2021, People power, DIABETIC MEDICINE, Vol: 38, ISSN: 0742-3071
Avari P, Unsworth R, Rilstone S, et al., 2021, Improved glycaemia during the Covid-19 pandemic lockdown is sustained post-lockdown and during the "Eat Out to Help Out" Government Scheme, in adults with Type 1 diabetes in the United Kingdom, PLoS One, Vol: 16, Pages: 1-13, ISSN: 1932-6203
AimsThe majority of studies report that the Covid-19 pandemic lockdown did not have a detrimental effect on glycaemia. We sought to explore the impact of lockdown on glycaemia and whether this is sustained following easing of restrictions.MethodsRetrospective, observational analysis in adults and children with type 1 diabetes attending a UK specialist centre, using real-time or intermittently scanned continuous glucose monitoring. Data from the following 28-day time periods were collected: (i) pre-lockdown; (ii) during lockdown; (iii) immediately after lockdown; and (iv) a month following relaxation of restrictions (coinciding with Government-subsidised restaurant food). Data were analysed for times in glycaemic ranges and are expressed as median (IQR).Results145 adults aged 35.5 (25.8–51.3) years with diabetes duration of 19.0 (7.0–29.0) years on multiple daily injections of insulin (60%) and continuous insulin infusion (40%) were included. In adults, % time in range (70-180mg/dL) increased during lockdown (60.2 (45.2–69.3)%) compared to pre-lockdown (56.7 (43.5–65.3)%; p<0.001). This was maintained in the post-lockdown time periods. Similarly, % time above range (>180mg/dL) reduced in lockdown compared to pre-lockdown (p = 0.01), which was sustained thereafter. In children, no significant changes to glycaemia were observed during lockdown. In multivariable analysis, a greater increase in %TIR 3.9-10mmol/L (70-180mg/dL) during lockdown was associated with higher levels of deprivation (coefficient: 4.208, 95% CI 0.588 to 7.828; p = 0.02).ConclusionsGlycaemia in adults improved during lockdown, with people from more deprived areas most likely to benefit. This effect was sustained after easing of restrictions, with government-subsidised restaurant eating having no adverse impact on glycaemia.
Thomas NJ, Dennis JM, Sharp SA, et al., 2021, DR15-DQ6 remains dominantly protective against type 1 diabetes throughout the first five decades of life, Diabetologia, Vol: 64, Pages: 2258-2265, ISSN: 0012-186X
Aims/hypothesisAmong white European children developing type 1 diabetes, the otherwise common HLA haplotype DR15-DQ6 is rare, and highly protective. Adult-onset type 1 diabetes is now known to represent more overall cases than childhood onset, but it is not known whether DR15-DQ6 is protective in older-adult-onset type 1 diabetes. We sought to quantify DR15-DQ6 protection against type 1 diabetes as age of onset increased.MethodsIn two independent cohorts we assessed the proportion of type 1 diabetes cases presenting through the first 50 years of life with DR15-DQ6, compared with population controls. In the After Diabetes Diagnosis Research Support System-2 (ADDRESS-2) cohort (n = 1458) clinician-diagnosed type 1 diabetes was confirmed by positivity for one or more islet-specific autoantibodies. In UK Biobank (n = 2502), we estimated type 1 diabetes incidence rates relative to baseline HLA risk for each HLA group using Poisson regression. Analyses were restricted to white Europeans and were performed in three groups according to age at type 1 diabetes onset: 0–18 years, 19–30 years and 31–50 years.ResultsDR15-DQ6 was protective against type 1 diabetes through to age 50 years (OR < 1 for each age group, all p < 0.001). The following ORs for type 1 diabetes, relative to a neutral HLA genotype, were observed in ADDRESS-2: age 5–18 years OR 0.16 (95% CI 0.08, 0.31); age 19–30 years OR 0.10 (0.04, 0.23); and age 31–50 years OR 0.37 (0.21, 0.68). DR15-DQ6 also remained highly protective at all ages in UK Biobank. Without DR15-DQ6, the presence of major type 1 diabetes high-risk haplotype (either DR3-DQ2 or DR4-DQ8) was associated with increased risk of type 1 diabetes.Conclusions/interpretationHLA DR15-DQ6 confers dominant protection from type 1 diabetes across the first five decades of life.
Oliver N, 2021, August Editorial 'People Power'., Diabet Med
Seismic international events, such as world wars and pandemics, have a global impact on healthcare that continues well beyond the duration of the event. Following the Spanish flu in 1918-1919 there was a baby boom, life expectancy increased, and socialized healthcare systems began to be established. In 1948, following the second world war, the NHS was established. The changes to healthcare that we will see following the Covid-19 pandemic will become apparent over the next few years but it is clear that models of care have already changed significantly and are unlikely to return to previous established pathways. In particular, remote care delivery has become established as a viable choice for people living with diabetes.
Ngaosuwan K, Johnston DG, Godsland IF, et al., 2021, Increased mortality risk in patients with primary and secondary adrenal insufficiency, Journal of Clinical Endocrinology and Metabolism, Vol: 106, Pages: e2759-e2768, ISSN: 0021-972X
CONTEXT: Mortality data in patients with adrenal insufficiency are inconsistent, possibly due to temporal and geographical differences between patients and their reference populations. OBJECTIVE: To compare mortality risk and causes of death in adrenal insufficiency with an individually-matched reference population. DESIGN: Retrospective cohort study. SETTING: UK general practitioner database (CPRD). PARTICIPANTS: 6821 patients with adrenal insufficiency (primary, 2052; secondary, 3948) and 67564 individually-matched controls (primary, 20366; secondary, 39134). MAIN OUTCOME MEASURES: All-cause and cause-specific mortality; hospital admission from adrenal crisis. RESULTS: With follow-up of 40799 and 406899 person-years for patients and controls respectively, the hazard ratio (HR; [95%CI]) for all-cause mortality was 1.68 [1.58 - 1.77]. HRs were greater in primary (1.83 [1.66 - 2.02]) than in secondary (1.52 [1.40 - 1.64]) disease; (HR; primary versus secondary disease, 1.16 [1.03 - 1.30]). The leading cause of death was cardiovascular disease (HR 1.54 [1.32-1.80]), along with malignant neoplasms and respiratory disease. Deaths from infection were also relatively high (HR 4.00 [2.15 - 7.46]). Adrenal crisis contributed to 10% of all deaths. In the first two years following diagnosis, the patients' mortality rate and hospitalisation from adrenal crisis were higher than in later years. CONCLUSION: Mortality was increased in adrenal insufficiency, especially primary, even with individual matching and was observed early in the disease course. Cardiovascular disease was the major cause but mortality from infection was also high. Adrenal crisis was a common contributor. Early education for prompt treatment of infections and avoidance of adrenal crisis hold potential to reduce mortality.
Oliver N, 2021, Outside in, DIABETIC MEDICINE, Vol: 38, ISSN: 0742-3071
Washirasaksiri C, Srivanichakorn W, Godsland IF, et al., 2021, Increasing glycaemia is associated with a significant decline in HDL cholesterol in women with prediabetes in two national populations, Scientific Reports, Vol: 11, ISSN: 2045-2322
Internationally, studies have shown associations between lipids and glycemia; however, whether the link varies by gender and population has been rarely examined. We investigated relationships between glycemia and HDL- and Non-HDL-cholesterol and their modification by gender. We undertook a cross-sectional analysis from the National Health Examination Survey for Thailand (NHES-Thailand) and the Health Survey for England (HS-England) in adults aged 18–75 year. Glycaemia was assessed by FPG in Thailand and by HbA1c in the UK. In population- and gender-stratified analyses, the relationships between glycemia and lipids were explored. A total of 15,145 Thai and 3484 UK adults with blood measurement were included. The prevalences of prediabetes were: in NHES-Thailand, 16% (SE = 0.004), based on FPG (5.6 to < 7.0 mmol/L) and in HS-England, 19% (0.007) based on HbA1c (39 to < 48 mmol/mol). Increasingly abnormal glucose homeostasis was associated with increasing age, adiposity, SBP, proportion of antihypertensive and lipid-lowering agent use and with decreasing HDL-cholesterol. Independent of age, adiposity, smoking, alcohol, physical activity, and lipid and BP lowering drug use, increasing glycemia was associated with decreasing HDL-cholesterol specifically in women with prediabetes (NHES-Thailand, beta-coefficient − 0.07 (95% CI − 0.15, − 0.001) p = 0.04 and HS-England, − 0.03 (− 0.04, − 0.006) p = 0.01). In both populations, among those with prediabetes, increasing glycaemia is associated with an adverse, significant decline in HDL cholesterol, specifically in women. These adverse effects are apparent in widely-differing international populations.
Miller A, Rilstone S, Oliver N, et al., 2021, EFFECT OF BLOOD GLUCOSE ON RATINGS OF PERCEIVED EXERTION DURING EXERCISE IN PEOPLE WITH DIABETES WHO UNDERTAKE REGULAR EXERCISE, Publisher: MARY ANN LIEBERT, INC, Pages: A120-A120, ISSN: 1520-9156
Avari P, Unsworth R, Uduku C, et al., 2021, IMPROVED GLYCAEMIA DURING THE COVID-19 LOCKDOWN IS SUSTAINED IN ADULTS WITH TYPE 1 DIABETES, Publisher: MARY ANN LIEBERT, INC, Pages: A200-A201, ISSN: 1520-9156
Unsworth R, Godsland I, Avari P, et al., 2021, THE EFFECT OF LOCKDOWN AND EASING OF RESTRICTIONS ON GLYCAEMIA IN CHILDREN WITH TYPE 1 DIABETES DURING THE COVID-19 PANDEMIC, Publisher: MARY ANN LIEBERT, INC, Pages: A200-A200, ISSN: 1520-9156
Avari P, Unsworth R, Rilstone S, et al., 2021, HIGHER LEVELS OF SOCIAL DEPRIVATION ASSOCIATED WITH INCREASED PERCENTAGE TIME IN RANGE IN PEOPLE WITH TYPE 1 DIABETES DURING COVID-19 LOCKDOWN, Publisher: MARY ANN LIEBERT, INC, Pages: A197-A197, ISSN: 1520-9156
Uduku C, Jugnee N, Pendolino V, et al., 2021, THE ASSESSMENT OF IMPACT OF REAL-TIME CONTINUOUS GLUCOSE MONITORING ON PEOPLE PRESENTING WITH SEVERE HYPOGLYCAEMIA (AIR-CGM) STUDY, Publisher: MARY ANN LIEBERT, INC, Pages: A197-A197, ISSN: 1520-9156
Herrero P, Armiger R, Daniels J, et al., 2021, AI UPGRADES AUTOMATED INSULIN DELIVERY TOWARDS A FULLY CLOSED-LOOP, Publisher: MARY ANN LIEBERT, INC, Pages: A4-A4, ISSN: 1520-9156
Herrero P, Reddy M, Georgiou P, et al., 2021, IDENTIFYING CGM DATA USING MACHINE LEARNING; A CGM DIGITAL 'FINGERPRINT', Publisher: MARY ANN LIEBERT, INC, Pages: A36-A36, ISSN: 1520-9156
Uduku C, Zhu T, Li K, et al., 2021, INDEPENDENT PREDICTORS OF HYPOGLYCAEMIA AND IMPENDING HYPOGLYCAEMIA USING A WEARABLE PHYSIOLOGICAL DATA ACQUISITION SENSOR, Publisher: MARY ANN LIEBERT, INC, Pages: A56-A57, ISSN: 1520-9156
Oliver N, 2021, Changes, DIABETIC MEDICINE, Vol: 38, ISSN: 0742-3071
Reddy M, Oliver N, 2021, Self-Monitoring of Blood Glucose Requirements with the Use of Intermittently Scanned Continuous Glucose Monitoring: A Follow-Up Analysis Using Real-Life Data, DIABETES TECHNOLOGY & THERAPEUTICS, Vol: 23, Pages: 392-396, ISSN: 1520-9156
- Author Web Link
- Cite
- Citations: 5
Ziegler R, Oliver N, Waldenmaier D, et al., 2021, Evaluation of the Accuracy of Current Tubeless Pumps for Continuous Subcutaneous Insulin Infusion, DIABETES TECHNOLOGY & THERAPEUTICS, Vol: 23, Pages: 350-357, ISSN: 1520-9156
- Author Web Link
- Cite
- Citations: 5
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.